A new study links private equity investments to higher costs; drugmakers profit from donations to patient charities; Medicare Advantage continues to grow; and, a reminder of the critical role that the Medicaid program has played during the ongoing coronavirus public health crisis.
You can keep up with the latest by following the Health Action Network on Twitter and by liking us on Facebook. And, be sure to check us out on LinkedIn, too. As always, let us know if there’s something you’d like to see covered in a future newsletter.
Final rules protecting consumers from surprise medical bills are released; employer healthcare costs are projected to rise; the majority of hospitals still fail to comply with federal price transparency requirements; and, the Medicaid program has become a vital safety net for rural communities.
Newly-launched prescription drugs head towards record-high prices; new research details the impact of hospital consolidation on prices and quality; private equity interests leave vulnerable rural communities exposed; and, Medicare Advantage helps millions of Americans overcome barriers.
A new report highlights the value of Medicare Advantage; hospital consolidation continues to reshape the care delivery landscape; elsewhere, nonprofit hospitals’ charity care is found to be lacking; and, Big Pharma’s patent abuse draws increased scrutiny.
A new report highlights the value of Medicare Advantage; hospital consolidation continues to reshape the care delivery landscape; elsewhere, nonprofit hospitals’ charity care is found to be lacking; and, Big Pharma’s patent abuse draws increased scrutiny.
A new report highlights the value of Medicare Advantage; hospital consolidation continues to reshape the care delivery landscape; elsewhere, nonprofit hospitals’ charity care is found to be lacking; and, Big Pharma’s patent abuse draws increased scrutiny.
Critical consumer protections from surprise medical bills face their latest test; a new legislative package seeks to address hospital consolidation; patent abuse keeps the price of inhalers artificially high; and, Medicare-eligible beneficiaries continue to choose Medicare Advantage plans.
Critical consumer protections from surprise medical bills face their latest test; a new legislative package seeks to address hospital consolidation; patent abuse keeps the price of inhalers artificially high; and, Medicare-eligible beneficiaries continue to choose Medicare Advantage plans.
Critical consumer protections from surprise medical bills face their latest test; a new legislative package seeks to address hospital consolidation; patent abuse keeps the price of inhalers artificially high; and, Medicare-eligible beneficiaries continue to choose Medicare Advantage plans.